menu search

EWTX / RBC Capital Says This Dystrophy Stock 'Is Worth A Look'

RBC Capital Says This Dystrophy Stock 'Is Worth A Look'
RBC Capital says Edgewise Therapeutics Inc's (NASDAQ: EWTX) interim results from the ARCH study of EDG-5506 in Becker Muscular Dystrophy (BMD) improve reward/risk into October functional readout at 15 mg, which can help further de-risk the asset into the phase 2 BMD. Read More
Posted: Jun 22 2022, 14:04
Author Name: Benzinga
Views: 111562

EWTX News  

Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 327.91%: Read This Before Placing a Bet

By Zacks Investment Research
September 5, 2023

Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 327.91%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 327.9% in Edgewise Therapeutics, Inc. (EWTX). While the effec more_horizontal

RBC Capital Says This Dystrophy Stock 'Is Worth A Look'

By Benzinga
June 22, 2022

RBC Capital Says This Dystrophy Stock 'Is Worth A Look'

RBC Capital says Edgewise Therapeutics Inc's (NASDAQ: EWTX) interim results from the ARCH study of EDG-5506 in Becker Muscular Dystrophy (BMD) im more_horizontal


Search within

Pages Search Results: